The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups

How to assess efficacy of interventions. In clinical practice, and particularly among those who appear to have mild liver disease, it may be sufficient to note changes(normalization) of liver tests and serum lipids/blood glucose in relation to lifestyle inter-vention and weight reduction. However, this is not sufficient for clinical trials because (i)liver pathology is not defined unless biopsy is performed and (ii) the only legitimate surro-gate marker for an improved clinical outcome of liver disease is improvement in liver fibrosis.